Product Description
Ipilimumab anti-CTLA-4) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor
[accordions]
[accordion title= “Cell Research“]
Objective: Ipilimumab augments antitumor activity of bispecific antibody-armed T cells. Concentrations: 0, 0.5, 5.0, and 50 μg/mL. Incubation Time: 10-14 days. Method: hPBMC were stimulated with anti-CD3 monoclonal antibody with or without ipilimumab and expanded for 10-14 days. ATC were harvested and armed with anti-CD3 x anti-EGFR BiAb (EGFRBi) or anti-CD3 x anti-CD20 BiAb (CD20Bi) to test for redirected cytotoxicity against COLO356/FG pancreatic cancer cell line or Burkitt’s lymphoma cell line (Daudi).
[/accordion]
[accordions]
[accordion title= “Animal Research“]
Objective: To investigate whether Ipilimumab and PD-1 antibody enhance the ability of T cells to control the outgrowth of EBV-induced lymphomas. Formulation: PBS. Dosages: 100 μg, three times weekly
[/accordion]
[accordions]
[accordion title= “References and Literature“]
1. Hu-Lieskovan S, et al. Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges. J Clin Oncol. 2014 Jul 20;32(21):2248-54.2. Giuseppe Tridente. Adverse Events with Biomedicines, 2013.3. Yano H, et al. Ipilimumab augments antitumor activity of bispecific antibody-armed T cells. J Transl Med. 2014 Jul 9;12:191.4. Selby MJ, et al. Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology. PLoS One. 2016 Sep 9;11(9):e01617795. Cui J, Yu J, Xu H, et al. Autophagy-lysosome inhibitor chloroquine prevents CTLA-4 degradation of T cells and attenuates acute rejection in murine skin and heart transplantation[J]. Theranostics. 2020, 10(18): 8051.
[/accordion]